Literature DB >> 12783421

The spectrum of autoimmune autonomic neuropathies.

Caroline M Klein1, Steven Vernino, Vanda A Lennon, Paola Sandroni, Robert D Fealey, Lisa Benrud-Larson, David Sletten, Phillip A Low.   

Abstract

We analyzed the clinical characteristics of 18 patients (13 female, 5 male) who had autoimmune autonomic neuropathy (AAN) and ganglionic acetylcholine receptor (AChR) autoantibodies. Mean age was 61.4 years (standard deviation, 12.0 years). Ten patients had subacute symptom onset, six with an antecedent event. Eight patients had chronic AAN, characterized by insidious symptom onset, without antecedent event, and gradual progression. A majority of patients with high antibody values (>1.00 nmol/L) had a combination of sicca complex (marked dry eyes and dry mouth), abnormal pupillary light response, upper gastrointestinal symptoms, and neurogenic bladder. Chronic AAN segregated into two subgroups. One subgroup (N = 4) had low antibody titer (0.09 +/- 0.01 nmol/L) and a paucity of cholinergic symptoms. It was indistinguishable from pure autonomic failure. The other subgroup (N = 4) had high antibody titer (11.6 +/- 2.08 nmol/L), sicca complex, abnormal pupils, and neurogenic bladder; three had severe upper gastrointestinal dysfunction. Higher antibody titers correlated with greater autonomic dysfunction and more frequent cholinergic dysautonomia. These observations expand the clinical spectrum of AAN to include chronic cases, some being indistinguishable from pure autonomic failure, and support the concept that ganglionic AChR antibodies are important diagnostically and pathophysiologically in acquired dysautonomia.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12783421     DOI: 10.1002/ana.10556

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  Paraneoplastic pandysautonomia as a manifestation of non-small cell lung cancer.

Authors:  Kayihan Uluc; Muge Kocak; Pinar Kahraman Koytak; Deniz Borucu; Baris Isak; Sevinc Aktan; Onder Us
Journal:  Neurol Sci       Date:  2010-05-08       Impact factor: 3.307

2.  Neural autoantibody evaluation in functional gastrointestinal disorders: a population-based case-control study.

Authors:  Sean J Pittock; Vanda A Lennon; Carissa L Dege; Nicholas J Talley; G Richard Locke
Journal:  Dig Dis Sci       Date:  2010-12-23       Impact factor: 3.199

Review 3.  Other autonomic neuropathies associated with ganglionic antibody.

Authors:  Paola Sandroni; Phillip A Low
Journal:  Auton Neurosci       Date:  2008-12-04       Impact factor: 3.145

4.  Characterization of ganglionic acetylcholine receptor autoantibodies.

Authors:  Steven Vernino; Jon Lindstrom; Steve Hopkins; Zhengbei Wang; Phillip A Low
Journal:  J Neuroimmunol       Date:  2008-05-15       Impact factor: 3.478

Review 5.  Prevalence of orthostatic hypotension.

Authors:  Phillip A Low
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

Review 6.  Pathophysiology and Individualized Management of Vasovagal Syncope and Postural Tachycardia Syndrome in Children and Adolescents: An Update.

Authors:  Ying Liao; Junbao Du
Journal:  Neurosci Bull       Date:  2020-05-04       Impact factor: 5.203

Review 7.  Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy.

Authors:  Steven Vernino; Steve Hopkins; Zhengbei Wang
Journal:  Auton Neurosci       Date:  2008-10-31       Impact factor: 3.145

Review 8.  Update on the theory and management of orthostatic intolerance and related syndromes in adolescents and children.

Authors:  Julian M Stewart
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-11

Review 9.  [Bladder dysfunction due to rare neurological disorders].

Authors:  S Schumacher; A Haferkamp; S C Müller
Journal:  Urologe A       Date:  2003-12       Impact factor: 0.639

10.  Sudomotor dysfunction in autoimmune autonomic ganglionopathy.

Authors:  K Kimpinski; V Iodice; P Sandroni; R D Fealey; S Vernino; P A Low
Journal:  Neurology       Date:  2009-11-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.